D2 Dopamine Receptor and Genes and Associated United States Patents
OHSU # 0165
Researchers at OHSU have cloned the D2 Dopamine receptor, and have developed cell lines containing both the D2 short and long forms, which are useful in studying ligand-receptor interactions, and developing potential drug candidates for treatment of neurological diseases. Currently, the university holds numerous patents covering the gene and protein sequences encoding for this receptor and its use as a target for drug development purposes, as well as methods for preparing labeled or unlabeled species for research and development.
Dopamine receptors have key roles in many processes, including the control of motivation, addiction and fine motor movement, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling in the central nervous system is implicated in several neuropsychiatric disorders, including Tourette's syndrome, Parkinson's disease, schizophrenia, Attention-deficit hyperactivity disorder, and drug and alcohol dependence. Thus, dopamine receptors are common drug targets for antipsychotics and psychostimulants.
The D2 short form and D2 long form of the receptor are available for non-exclusive licensing as stable transfectants in HEK cells. They are functional in cAMP assays looking at the inhibition of FSK stimulation. The receptor is tagged with an M1 Flag epitope and, using antibodies to the epitope, show high levels of expression in immunoflourescence characterization.
This technology ID # 0165 covers all uses of the Dopamine D2 receptor under US patents.
Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci. 1989 Dec.86(24):9762-6.
Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988 Dec 22-29;336(6201):783-7.
- Olivier Civelli
- James Bunzow, VI.Vollum Institute
- David Grandy, SM.Physiology & Pharmacology
- Curtis Machida, SD.Integrative Biosciences
|Issued||United States||6,277,591 B1|
- OHSU # 0134 — D2 Dopamine Receptor and Genes and Associated International Patents
- Biological Materials - Receptors/Targets
- Research Tools - Screening
- Biological Materials
- Research Tools
For more information, contact:
Technology Development Manager